Identifying a Cancer Marker in Prostate Cancer
Author Information
Author(s): Li Geng, Assudani Deepak P, Line Aija, Cao Fuming, Miles Amanda, Rees Robert C, McArdle Stephanie E.B
Primary Institution: Nottingham Trent University
Hypothesis
Can serological screening of prostate cancer cDNA libraries identify specific tumor antigens?
Conclusion
The study identified MTA1 as a potential biomarker and therapeutic target for aggressive prostate cancer.
Supporting Evidence
- The study identified 54 distinct genes, including 46 known and 8 previously uncharacterized.
- MTA1 was found to be over-expressed in various cancer tissues compared to normal tissues.
- MTA1 transcripts were detected in all murine tumor cell lines tested.
Takeaway
Researchers looked for special proteins in prostate cancer that could help doctors find and treat the disease better. They found one called MTA1 that might be really important.
Methodology
The study used serological analysis of recombinant cDNA expression libraries (SEREX) to identify tumor antigens from prostate cancer tissues.
Limitations
The study did not establish the immunogenicity of all identified antigens and relied on a limited sample size.
Participant Demographics
Included prostate cancer patients and healthy male volunteers.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website